Home › Compare › PKBO vs EQR

PKBO vs EQR: Dividend Comparison 2026

PKBO yields 8888.89% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PKBO wins by $17290949737713800.00M in total portfolio value
10 years
PKBO
PKBO
● Live price
8888.89%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17290949737713800.00M
Annual income
$16,916,578,202,775,594,000,000.00
Full PKBO calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — PKBO vs EQR

📍 PKBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKBOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKBO + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PKBO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKBO
Annual income on $10K today (after 15% tax)
$755,555.56/yr
After 10yr DRIP, annual income (after tax)
$14,379,091,472,359,256,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, PKBO beats the other by $14,379,091,472,359,256,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKBO + EQR for your $10,000?

PKBO: 50%EQR: 50%
100% EQR50/50100% PKBO
Portfolio after 10yr
$8645474868856900.00M
Annual income
$8,458,289,101,387,797,000,000.00/yr
Blended yield
97.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PKBO
No analyst data
Altman Z
13837.7
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKBO buys
0
EQR buys
0
No recent congressional trades found for PKBO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKBOEQR
Forward yield8888.89% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$17290949737713800.00M ✓$47.8K
Annual income after 10y$16,916,578,202,775,594,000,000.00 ✓$5,475.61
Total dividends collected$17265985963886318.00M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PKBO vs EQR ($10,000, DRIP)

YearPKBO PortfolioPKBO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$899,589$888,888.89$11,380$679.82+$888.2K → PKBO
2$75,694,763$74,732,202.61$13,014$837.25+$75.68M → PKBO
3$5,957,858,933$5,876,865,536.53$14,961$1,036.20+$5957.84M → PKBO
4$438,676,028,838$432,301,119,780.33$17,297$1,289.22+$438676.01M → PKBO
5$30,217,280,421,144$29,747,897,070,286.80$20,121$1,613.15+$30217280.40M → PKBO
6$1,947,399,451,993,550$1,915,066,961,942,926.00$23,561$2,030.84+$1947399451.97M → PKBO
7$117,429,004,658,116,600$115,345,287,244,483,520.00$27,783$2,573.54+$117429004658.09M → PKBO
8$6,625,994,131,926,989,000$6,500,345,096,942,805,000.00$33,013$3,284.39+$6625994131926.96M → PKBO
9$349,879,939,194,586,330,000$342,790,125,473,424,500,000.00$39,547$4,223.51+$349879939194586.25M → PKBO
10$17,290,949,737,713,800,000,000$16,916,578,202,775,594,000,000.00$47,791$5,475.61+$17290949737713800.00M → PKBO

PKBO vs EQR: Complete Analysis 2026

PKBO — Stock

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Full PKBO Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PKBO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKBO vs SCHDPKBO vs JEPIPKBO vs OPKBO vs KOPKBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.